MODIFICATION
A -- RFP: Procurement of Filovirus Medical Countermeasures
- Notice Date
- 5/16/2022 2:18:45 PM
- Notice Type
- Solicitation
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- BARDA - ASPR / DAAPPO / BARDA DCMA WASHINGTON DC 20515 USA
- ZIP Code
- 20515
- Solicitation Number
- 75A50122R00006
- Response Due
- 7/6/2022 7:00:00 AM
- Archive Date
- 07/07/2022
- Point of Contact
- Jonathan Gonzalez, Jennifer Taranto
- E-Mail Address
-
Jonathan.Gonzalez@hhs.gov, jennifer.taranto@hhs.gov
(Jonathan.Gonzalez@hhs.gov, jennifer.taranto@hhs.gov)
- Description
- Infections by Ebola (EBOV), Sudan (SUDV), and Marburg (MARV) viruses result in a highly lethal Viral Hemorrhagic Fever (VHF) with mortality ranging from 25-90 percent depending on the outbreak and the virus species by which it was caused. The 2014-2016 EBOV epidemic in West Africa highlighted the threat filoviruses pose to public health, with greater than 28,000 confirmed cases and more than 11,300 deaths. The United States Government (USG) has supported numerous responses to naturally occurring outbreaks of EBOV and MARV and additionally these agents pose a threat to national security if purposely released as a biological weapon. Procurement of filovirus therapeutics is urgently needed to enable the USG�s preparedness and response to public health emergencies and to mitigate the threat of biological attacks. In� order� to� address this unmet need,� the� Office� of� the� Biomedical� Advanced� Research� and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) intends to use Project BioShield (PBS) to support the late-stage development and procurement of therapeutics against EBOV, SUDV, or MARV. The� procured�� therapeutics will either be delivered to the ASPR/Strategic National Stockpile or maintained as� vendor� managed� inventory.� The� USG� seeks therapeutics� that���� meet� the���� following���� mandatory����� criteria: 1)����� The����� Offeror must�� have submitted��� an�� investigational��� new��� drug��� (IND)�� application��� related��� to�� the� intended operational� use� of� a� product� as� a�� filovirus�� therapeutic;�� and�� 2)�� The Offeror� must have�� documented�� FDA concurrence on the proposed regulatory path leading�� to approval of the product as a filovirus therapeutic.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/36ed6711b4644e4b9da6078cd6957069/view)
- Place of Performance
- Address: USA
- Country: USA
- Country: USA
- Record
- SN06327713-F 20220518/220516230058 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |